223 related articles for article (PubMed ID: 9127173)
1. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.
Friess H; Gassmann M; Büchler MW
Int J Pancreatol; 1997 Feb; 21(1):43-52. PubMed ID: 9127173
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.
Tempero MA; Haga Y; Sivinski C; Steplewski Z; Kay HD; Pour P
Int J Pancreatol; 1991; 9():125-34. PubMed ID: 1744438
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.
Schulz G; Büchler M; Muhrer KH; Klapdor R; Kübel R; Harthus HP; Madry N; Bosslet K
Int J Cancer Suppl; 1988; 2():89-94. PubMed ID: 3162451
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of pancreatic carcinoma.
Märten A
Rev Recent Clin Trials; 2008 May; 3(2):121-5. PubMed ID: 18474022
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for pancreatic cancer: A long and hopeful journey.
Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
[TBL] [Abstract][Full Text] [Related]
8. Biological response modifier--immunotherapeutic approaches in pancreatic cancer.
Schmiegel W
Hepatogastroenterology; 1989 Dec; 36(6):456-8. PubMed ID: 2693301
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
Büchler M; Friess H; Schultheiss KH; Gebhardt C; Kübel R; Muhrer KH; Winkelmann M; Wagener T; Klapdor R; Kaul M
Cancer; 1991 Oct; 68(7):1507-12. PubMed ID: 1654194
[TBL] [Abstract][Full Text] [Related]
10. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
Paul AR; Engstrom PF; Weiner LM; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S171-4. PubMed ID: 3527946
[TBL] [Abstract][Full Text] [Related]
12. What is recent in pancreatic cancer immunotherapy?
Niccolai E; Prisco D; D'Elios MM; Amedei A
Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.
Tempero MA; Pour PM; Uchida E; Herlyn D; Steplewski Z
Hybridoma; 1986 Jul; 5 Suppl 1():S133-8. PubMed ID: 3744378
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the treatment of pancreatic cancer.
Huang ZQ; Buchsbaum DJ
Immunotherapy; 2009 Mar; 1(2):223-9. PubMed ID: 20046965
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Büchler M; Kübel R; Malfertheiner P; Friess H; Schulz G; Bosslet K; Beger HG
Dtsch Med Wochenschr; 1988 Mar; 113(10):374-80. PubMed ID: 3349938
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
19. The role of adjuvant therapy for pancreatic cancer.
Magee CJ; Ghaneh P; Hartley M; Sutton R; Neoptolemos JP
Expert Opin Investig Drugs; 2002 Jan; 11(1):87-107. PubMed ID: 11772324
[TBL] [Abstract][Full Text] [Related]
20. [Immunoscintigraphy of colorectal cancers and specific immunotherapy of pancreatic cancers using monoclonal antibodies].
Bosslet K; Schwarz A; Steinstraesser A; Kuhlmann L; Seidel L; Schulz G
Wien Med Wochenschr; 1988 Jun; 138(11-12):255-7. PubMed ID: 3262953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
